Prevention of remodeling of the heart after myocardial infarction.
Secondary prevention is critical following myocardial infarction. Infarct expansion leads to cardiomegaly, which may adversely affect prognosis. Infarct expansion seems to be associated with hypertension, anterior location, persistent (probably sudden) occlusion of the infarct artery, and poor collateralization. Prevention of cardiomegaly by angiotensin-converting-enzyme inhibitors, and possibly nitrates, seems to improve survival. Angiotensin-converting-enzyme inhibitors seem to delay the onset and the frequency of congestive failure and recurrent myocardial infarction.
Gorlin
R
R
Mount Sinai Medical Center, New York 10029, USA.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D006332:Cardiomegaly / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003097:Collateral Circulation; D004452:Echocardiography; D004562:Electrocardiography; D006333:Heart Failure / Q000209:etiology; D006439:Hemodynamics; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000503:physiopathology* / Q000517:prevention & control; D009566:Nitrates / Q000627:therapeutic use; D011379:Prognosis; D016019:Survival Analysis; D015912:Thrombolytic Therapy; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D009566:Nitrates